All-Cause, CVD Mortality Down With Light, Moderate Drinking

Share this content:
All-Cause, CVD Mortality Down With Light, Moderate Drinking
All-Cause, CVD Mortality Down With Light, Moderate Drinking

MONDAY, Aug. 14, 2017 (HealthDay News) -- All-cause and cardiovascular disease (CVD) mortality are reduced for U.S. adults with light and moderate alcohol intake, according to a study published in the Aug. 22 issue of the Journal of the American College of Cardiology.

Bo Xi, M.D., from the School of Public Health at Shandong University in Jinan, China, and colleagues obtained data by linking 13 waves of the National Health Interview Surveys to the National Death Index records. Data were included for 333,247 participants aged 18 years and older.

The researchers found that 34,754 participants died of all causes after a median follow-up of 8.2 years. Those who were light or moderate alcohol consumers, compared with lifestyle abstainers, had a reduced risk of all-cause mortality (hazard ratios, 0.79 and 0.78 for light and moderate drinkers, respectively) and CVD mortality (hazard ratios, 0.74 and 0.71, respectively). For adults with heavy alcohol consumption, mortality was increased significantly for all causes and cancer (hazard ratios, 1.11 and 1.27, respectively). Increased risk of mortality for all causes and cancer was seen in association with binge drinking one or more days/week (hazard ratios, 1.13 and 1.22, respectively).

"Light and moderate alcohol intake might have a protective effect on all-cause and CVD-specific mortality in U.S. adults," the authors write. "Heavy or binge drinking was associated with increased risk of all-cause and cancer-specific mortality."

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »